The R-SNARE Endobrevin/VAMP-8 Mediates Homotypic Fusion of Early Endosomes and Late Endosomes

Wolfram Antonin,*† Claudia Holroyd,*† Ritva Tikkanen,‡ Stefan Hönig,§ and Reinhard Jahn †

†Department of Neurobiology, Max-Planck-Institute for Biophysical Chemistry, Göttingen, Germany; ‡Institute for Cell Biology, University of Bonn, Bonn, Germany; and §Institute for Biochemistry II, University of Göttingen, Göttingen, Germany

Submitted January 12, 2000; Revised April 24, 2000; Accepted July 27, 2000
Monitoring Editor: Suzanne R. Pfeffer

Endobrevin/VAMP-8 is an R-SNARE localized to endosomes, but it is unknown in which intracellular fusion step it operates. Using subcellular fractionation and quantitative immunogold electron microscopy, we found that endobrevin/VAMP-8 is present on all membranes known to communicate with early endosomes, including the plasma membrane, clathrin-coated pits, late endosomes, and membranes of the trans-Golgi network. Affinity-purified antibodies that block the ability of endobrevin/VAMP-8 to form SNARE core complexes potently inhibit homotypic fusion of both early and late endosomes in vitro. Fab fragments were as active as intact immunoglobulin Gs. Recombinant endobrevin/VAMP-8 inhibited both fusion reactions with similar potency. We conclude that endobrevin/VAMP-8 operates as an R-SNARE in the homotypic fusion of early and late endosomes.

INTRODUCTION

Trafficking of intracellular membranes involves the fusion of vesicles with their respective target membranes. Intracellular fusion events are mediated by complementary sets of SNARE proteins that are localized on the membranes destined to fuse (Rothman, 1994). SNAREs constitute a superfamily of proteins that share a common motif (the SNARE motif of ~60–70 amino acids) (Jahn and Südhof, 1999). The best characterized SNAREs are those functioning in exocytosis of synaptic vesicles. They include the vesicle protein synaptobrevin (also referred to as VAMP) and the plasma membrane proteins syntaxin 1 and SNAP-25. These proteins assemble spontaneously into a ternary complex that is disassembled by the chaperone ATPase NSF (NEM [N-ethylmaleimide]-sensitive factor) in conjunction with cofactors called SNAPs (soluble NSF attachment proteins) (Söllner et al., 1993). According to a current model, the assembly drives the fusion reaction by forming a tight connection between the SNAREs in the partner membranes (trans complexes). After fusion, the SNAREs within the complex are all aligned in parallel (cis complexes). They then need to be reenergized for another round of fusion by NSF and ATP-mediated disassembly (Hanson et al., 1997).

Sequence comparison revealed that all known SNARE motifs fall into two major subfamilies that contain either a conserved glutamine (Q-SNAREs) or a conserved arginine (R-SNAREs) at a central position (Fasshauer et al., 1998b; Weimbs et al., 1998). In the neuronal SNARE complex, three Q-SNARE motifs (one contributed by syntaxin and two by SNAP-25) and one R-SNARE motif (contributed by synaptobrevin/VAMP) form an extended helical bundle (Sutton et al., 1998). The glutamines and the arginine interact to form an ionic layer in the middle of the helical bundle that is surrounded by less well conserved hydrophobic layers. A similar composition of three Q-SNAREs and one R-SNARE was also found in a corresponding SNARE complex of yeast. Together, these observations suggest that all SNARE complexes consist of such four-helix bundles (three Q-SNARE motifs, one R-SNARE motif) with an asymmetric ionic layer in the middle.

SNARE complexes other than those functioning in exocytosis of neurons and yeast, however, are less well characterized. For instance, in yeast the homotypic fusion of vacuole precursors is probably mediated by the SNAREs Nyv1p, Vam7p, and Vam3p (Nichols et al., 1997; Ungermann and Wickner, 1998), and possibly also Vti1p (Götte and von Mollard, 1998). Similarly, the SNAREs Sed5p, Sec22p, Bet1p,
and Bos1p are candidates for the fusion of endoplasmic reticulum (ER)-derived trafficking vesicles with the cis-Golgi, but some of these proteins may also be involved in retrograde traffic from the cis-Golgi to the ER (Spang and Schekman, 1998). In mammalian cells, the Sed5 orthologue syntaxin 5 has been shown to be required for the fusion of ER-derived trafficking vesicles (Dascher et al., 1994; Dascher and Balch, 1996) with the Golgi apparatus as well as for the reassembly of Golgi stacks after mitosis (Rabouille et al., 1998).

Recently, many novel SNAREs have been identified, mostly as a result of the rapid growth of expressed sequence tag databases (Bock and Scheller, 1997). Most of them appear to be localized to specific subsets of intracellular membranes, suggesting that they specifically mediate distinct fusion steps (for review, see Jahn and Südhof, 1999). However, a precise subcellular localization of a given SNARE is a prerequisite, but it is by no means sufficient to pinpoint the fusion step in which it functions. Every trafficking vesicle derived from a donor compartment carries SNAREs required for fusion with its target membrane. Because after fusion the SNAREs need to recycle to the donor compartment, they must be present not only in the donor and target compartments but also in all intermediates involved in the recycling pathway and, furthermore, in the membranes involved in its biogenesis. It is essential, therefore, to map a given SNARE precisely on intracellular recycling pathways before hypotheses about the fusion step it mediates can be proposed.

In the present study, we have focused on the role of a recently discovered R-SNARE, endobrevin/VAMP-8 (Advani et al., 1998; Wong et al., 1998b). Endobrevin is only distantly related to the synaptobrevins and appears to be localized mainly to an early endosomal compartment. We now report that in addition to early endosomes, endobrevin is present on late endosomes and the trans-Golgi network (TGN) as well as on coated pits and the plasma membrane, suggesting that it recycles by means of two distinct pathways. In line with this intracellular distribution, our data document that endobrevin functions as an R-SNARE in the homotypic fusion of both early and late endosomes.

**MATERIALS AND METHODS**

**Materials**

Rat syntaxin 1A (residues 1–265) in a pET22b vector encoding for a factor Xa-cleavable C-terminal His6 fusion protein and a thrombin-cleavable GST-endobrevin (residues 1–74) expression construct (rabbit antiserum G96) (Jahn et al., 1985); cellubrevin (rabbit antiserum R54) (Annaert et al., 1997); endobrevin (rabbit antiserum) (Fasshauer et al., 1999); rab5 (mAb Cl 621.3) (Fischer von Mollard et al., 1994); and rab6 (rabbit antiserum R6) (Fischer von Mollard et al., 1994). The following antibodies were kind gifts: syntaxin (mAb HPC-1; provided by Dr. C. Barnstable, Yale School of Medicine, New Haven, CT) (Barnstable et al., 1985); Sec1α (rabbit serum; provided by Dr. E. Hartmann, University of Göttingen, Göttingen, Germany) (Görlich et al., 1992); LIMP II (rabbit antiserum and mAb provided by Y. Tenaka, Kyushu University, Fukuoka, Japan) (Barrio et al., 1986); and MPR46 (rabbit serum MSC1; provided by A. Hille-Rehfeld, University of Göttingen, Göttingen, Germany). SCAMP (rabbit serum) was obtained from Synaptic Systems (Göttingen, Germany).

**Preparation of Fab Fragments**

Synaptophysin antiserum was affinity purified as described (Navone et al., 1986). Endobrevin antiserum was affinity purified with the use of recombinant GST–endobrevin (Fasshauer et al., 1999) coupled to cyanogen bromide-Sepharose 4B (Pharmacia, Piscataway, NJ).

Affinity-purified antibodies against endobrevin and synaptophysin were digested with the use of papain beads (Sigma Chemical, St. Louis, MO) for 90 min at 37°C in PBS containing 1 mM EDTA and 10 mM cysteine, pH 7.4. The beads were then pelleted at 14,000 × g for 5 min. Antipain and PMSF were added to the supernatant at final concentrations of 2 μg/ml and 0.5 μM, respectively. Fab fragments were purified by ion exchange chromatography with the use of a Mono-Q column in a fast-performance liquid chromatography (TGF) and pooled fractions were tested by SDS-PAGE/immunoblotting for the presence of Fab fragments and undigested immunoglobulin (IgGs). The Fab fragment containing fractions were free of IgGs, IgMs, or digestive products. The purified Fab fragments exhibited an affinity similar to that of undigested IgGs when tested by immunoblotting in serial dilutions.

**Subfractionation and Immunooisolation of Endosomes**

For separation of early and late endosomes, postnuclear supernatants (PNS) were fractionated with the use of isopycnic sucrose density gradient centrifugation. PNS were adjusted to 42% sucrose and overlaid with a discontinuous sucrose gradient according to Aniento et al. (1993). When the separation was performed after the fusion reaction, the incubation mix was loaded directly on top of a continuous sucrose gradient (10–40% [wt/vol] dissolved in 3 mM HEPES, pH 7.4, 0.5 mM EDTA, 1 μg/ml biotinylated insulin [Sigma; added as quencher]) and centrifuged for 19 h at 40,000 rpm in a Beckman (Fullerton, CA) SW 41 rotor.

For immunooisolation, mAb Cl 621.3 (anti-Rab5) and affinity-purified anti-endobrevin antibodies were covalently coupled to Eupergit C12 methacrylate microbeads as described (Burger et al., 1989). Liver was homogenized in homogenization buffer (320 mM sucrose, 5 mM HEPES, pH 7.4, 1 mM EDTA, 0.1 mM GTPyS, and the following protease inhibitors: 10 μg/ml soybean trypsin inhibitor, 1 μg/ml pepstatin, 11 μg/ml benzamidine, 1 μg/ml antipain, 1 μg/ml leupeptin, 0.1 mM PMSF) with the use of a glass–Teflon homogenizer (five strokes, 600 rpm). PNS was generated by centrifugation at 1000 × g for 10 min. PNS (200 μg of protein) was incubated in 400 μl of homogenization buffer with 20 μl of the appropriate beads for 1 h at 4°C. The incubation mixture was layered on top of a sucrose cushion (0.5 ml, 0.8 M) and centrifuged for 5 min at 4600 × g. The supernatants were centrifuged at 30 min at 200,000 × g at 4°C with the use of a Beckman TL102.2 rotor to sediment nonbound membranes. The bead pellets were washed five times with PBS. Aliquots of each sample as well as the starting PNS were analyzed by SDS-PAGE and immunoblotting. For detection of Rab5, a rabbit serum (R6) was used with protein A coupled to HRP (Sigma) as a secondary antibody to exclude interference by bead-derived antibodies.

**Cell-free Fusion Assay**

For measuring endosome fusion, sets of cells were allowed to internalize biotinylated HRP and avidin, respectively. Upon mixing of PNS, endosome fusion yields a tight complex between avidin and...
biotinylated peroxidase, which is quantitated after immunoprecipitation (Gruenberg et al., 1989).

Fluid-phase internalization for labeling of early endosomes of PC12 cells (Greene and Tischler, 1976) was performed as described (Holroyd et al., 1999). For late endosomes, the labeling time was increased to 20 min followed by five washes for 5 min with PBS supplemented with 1 mM MgCl₂, 1 mM CaCl₂, and 0.5% BSA and a 60-min chase in marker-free medium supplemented with 0.2% BSA.

The assay for in vitro fusion of early endosomes of PC12 cells was performed as described (Holroyd et al., 1999). The assay for late endosome fusion was identical except that labeling and chase times were changed as described above. The reaction mixtures were increased to 200 μl (final volume). Where indicated, both PNS fractions were incubated separately with 6 mg of purified Fab fragments or with recombinant protein (30 μM final concentration) at 37°C for 10 min before combining donor and acceptor PNS fractions for the fusion reaction. For preincubation with cytosol, donor and acceptor PNS were incubated with the appropriate Fab fragments, cytosol, assay buffer, and an ATP-generating system in a final volume of 100 μl. Recombinant synaptobrevin (residues 1–96) (Fasshauer et al., 1998a) and endobrevin (residues 1–74) (Fasshauer et al., 1999) were purified as described. All fusion activities were corrected for the activities measured in the absence of ATP (usually <1% of the ATP-dependent activities).

**In Vitro Assembly of SNARE Proteins**

One microgram of recombinant endobrevin (residues 1–74) (Fasshauer et al., 1999) was preincubated with 20 μg of affinity-purified antibodies specific for endobrevin and synaptophysin or with 7 μg of the corresponding Fab fragments for 15 min at room temperature. To each sample, 7.5 μg of purified binary complex consisting of SNAP-25 and the cytoplasmic region of syntaxin 1 (residues 1–265) (Fasshauer et al., 1999) was added and incubated for 10 h at 4°C. As an assay for assembly, the formation of a SDS-resistant complex of endobrevin, syntaxin1, and SNAP-25 was monitored by SDS-PAGE and immunoblotting with the use of the antibody HPC-1 specific for syntaxin-1.

**Electron Microscopy**

Immunoelectron microscopy was performed according to the Tokuyasu method (Tokuyasu, 1973; Slot and Geuze, 1985). Nature rat kidney (NRK) cells were incubated for 15 min with BSA coupled to 5-nm gold (BSA-gold) before fixation. The cells were fixed for 2 h on ice with 2% paraformaldehyde and 0.2% glutaraldehyde in 0.1 M K-phosphate buffer, pH 7.3, and embedded into 10% gelatin. Small blocks were immersed in 2.3 M sucrose overnight for cryoprotection. Ultrathin cryosections were cut from the frozen samples and collected from the diamond knife with a mixture of methylcellulose and sucrose (Liou et al., 1996). The sections were labeled with primary antibodies and detected with protein A–gold purchased from the laboratory of H. Geuze (Utrecht University, Utrecht, the Netherlands). Immunolabeled sections were contrasted with uranyl acetate and embedded into uranyl-methyl cellulose and viewed with a Philips (Eindhoven, the Netherlands) CM120 electron microscope at 80 kV.

**RESULTS**

**Endobrevin/VAMP-8 Is an Abundant Resident of Early and Late Endosomes**

For the characterization of endobrevin, we generated rabbit antisera with the use of bacterially expressed protein. These sera reacted with a single band corresponding to endobrevin in cell extracts (Fasshauer et al., 1999). For further characterization, endobrevin-specific antibodies were affinity-purified with the use of immobilized endobrevin as affinity matrix.

We first determined the distribution of endobrevin within the endocytic pathway from the plasma membrane to lyso-
somes. NRK cells were incubated with BSA-gold as an endocytic marker for 15 min to label endocytic compartments. The cells were then fixed and analyzed by immunoelectron microscopy of cryosections. Endobrevin labeling was detectable in tubulovesicular structures, small vesicles (Figure 1A, arrow), and endosomes of vacuolar type (Figure 1A) in agreement with Wong et al. (1998b). In addition, endobrevin was found together with BSA-gold in multivesicular bodies (Figure 1B).

To obtain a more detailed overview of the distribution of endobrevin, we performed a quantitative analysis of ultrathin frozen sections labeled for endobrevin. For comparison, the sections were double-labeled for LIMP II, a lysosomal type-3 membrane protein that is also distributed within endosomes (Barriocanal et al., 1986). In NRK cells, the biosynthetic pathway of LIMP II from the TGN to lysosomes is believed to involve endosomes bypassing the plasma membrane (Barriocanal et al., 1986; R. Tikkanen and S. Höning, unpublished data). Endobrevin was abundantly present on tubulovesicular structures near the plasma membrane (Figure 1, Table 1) and on multivesicular bodies and vacuolar endosomes (Figures 1 and 2, Table 1). On the latter compartments, a significant degree of colocalization with LIMP II was observed: >70% of the endobrevin-positive structures were also labeled for LIMP II (Table 1). In contrast, only small amounts of LIMP II labeling were detectable on endobrevin-positive tubulovesicular structures near the plasma membrane. When sections labeled for the endogenous MPRA6 (Hille-Rehfeld, 1995) and endobrevin were examined, a significant colocalization of endobrevin with MPRA6 in TGN-associated structures was observed (Figure 2B, arrowheads). In addition, endobrevin was detectable at the plasma membrane, in agreement with Wong et al. (1998b), and occasionally in clathrin-coated pits (Figure 2C).

Together, these data show that endobrevin is abundantly present on both early and late endosomes. In addition, the presence on the plasma membrane and coated pits indicates that endobrevin may also recycle via the plasma membrane. Endobrevin does not colocalize with the transferrin receptor (our unpublished results; see also Advani et al., 1998), indicating that recycling endosomes are largely devoid of the protein.

To examine the association of endobrevin with early and late endosomes by means of an independent approach, we immunosolated organelles containing endobrevin and analyzed them for the presence of endosomal markers. For comparison, we also isolated Rab5-containing organelles. Rab5 is regarded as one of the most specific markers for early endosomes (Novick and Zerial, 1997). For immunosolation, antibodies for endobrevin and Rab5 were immobilized on methacrylate microbeads (Eupergit C1Z). Immunobeads were incubated with excess amounts of PNS obtained from rat liver. Under these conditions, antigen-containing membranes are partially depleted, whereas the beads are saturated. This procedure was previously shown to yield organelles of exceptional purity with minimal contamination by other subcellular membranes (Burger et al., 1989; Fischer von Mollard et al., 1994). After isolation of the beads, the unbound membranes were collected by high-speed centrifugation and used as reference. As shown in Figure 3, both Rab5 beads– and endobrevin beads–bound membranes contained their respective antigens. About 50% of the antigen-containing membranes present in the starting material were bound. Rab5 beads–bound membranes contained endobrevin and endobrevin beads–bound membranes contained Rab5, confirming the association of endobrevin with early endosomes. Interestingly, however, membranes bound to endobrevin beads contained relatively less SCAMP and cellubrevin than membranes bound to Rab5 beads. SCAMP (Brand and Castle, 1993) and cellubrevin (McMahon et al., 1993) recycle between early endosomes and the plasma membrane and are thought to be sorted away from late endosomal/lysosomal compartments. Possibly, there are pools of cellubrevin/SCAMP-containing membranes that contain rab5 but are reduced or devoid of endobrevin, e.g., in the exocytotic limb of the recycling pathway that is highly amplified in liver. In contrast, LIMP II was relatively more enriched on endobrevin beads than on Rab5 beads, confirming the association of endobrevin with LIMP II–containing organelles. Sec61alpha, a component of the protein translocation complex of the ER (Görlich and Rapoport, 1993), did not bind to the beads, demonstrating the specificity of the immunosolation procedure. Furthermore, none of the proteins bound to beads containing no antibodies (control beads).

**Endobrevin/VAMP-8 Functions in Fusion of Both Early and Late Endosomes**

The data described above show that endobrevin is widely distributed within the endocytic pathway extending from the plasma membrane to early and late endosomes. In addition, smaller pools of endobrevin are also present on TGN-associated membranes, which may reflect either newly syn-

---

**Table 1. Quantification of endobrevin in NRK cells**

<table>
<thead>
<tr>
<th>Compartment</th>
<th>Percent gold particles</th>
<th>Of these, percent positive for LIMP II</th>
<th>LIMP II in NRK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Golgi/TGN</td>
<td>12</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Tubules, vesicles not assigned to TGN or PM</td>
<td>18</td>
<td>14</td>
<td>8</td>
</tr>
<tr>
<td>Tubulovesicular structures near PM</td>
<td>26</td>
<td>15</td>
<td>8</td>
</tr>
<tr>
<td>PM</td>
<td>8</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>MVBS/vacuolar endosomes, ATVs</td>
<td>29</td>
<td>71</td>
<td>72</td>
</tr>
<tr>
<td>Unclassified</td>
<td>7</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>

The cells were fixed and labeled for endobrevin and LIMP II as described in MATERIALS AND METHODS. For quantification, 34 sections were analyzed, and a total of 2800 gold particles were counted. PM, plasma membrane; MVBS, multivesicular bodies; ATVs, associated tubules and vesicles.
thesized protein en route to its destination or a recycling intermediate of the protein. Thus, endobrevin resides on membranes of two recycling pathways that overlap in the endosomal compartment: the first between early endosomes and the plasma membrane, and the second between early and late endosomes/lysosomes, possibly involving the TGN. Each of these pathways involves several distinct fusion and budding steps.

Because the highest concentrations of endobrevin were found on early and late endosomal compartments, we asked whether the protein may be involved in fusion of early and/or late endosomes. These fusion reactions are well characterized now that convenient in vitro assays are available. Both fusion reactions require NSF and ATP and thus are likely to be mediated by SNARE proteins (Robinson et al., 1997). They are distinguished by their preference for the partner membrane, by their requirements for specific Rab proteins (Gorvel et al., 1991; Feng et al., 1995), and probably also by their dependence on Rab-interacting proteins (Stenmark et al., 1995; Horiuchi et al., 1997; Simonsen et al., 1998).

To examine whether endobrevin functions in one of these fusion reactions, we used affinity-purified antibodies as a tool for blocking its SNARE function. Because assembly of cognate SNAREs into core complexes is currently thought to be the decisive step in driving membrane fusion, we first investigated whether the antibodies inhibited the ability of endobrevin to form SDS-resistant complexes. The cognate SNARE partners of endobrevin are not known at present. However, recent evidence has shown that endobrevin can substitute for synaptobrevin in neuronal SNARE complexes.

Figure 2. Immunogold localization of endobrevin and LIMP II. Ultrathin cryosections of NRK cells were immunolabeled for endobrevin (15-nm protein A–gold) and either LIMP II (10-nm protein A–gold; A) or the endogenous MPR46 (10-nm protein A–gold; B and C). Endobrevin is detectable in tubulovesicular structures (arrows in A), underneath the plasma membrane (PM), and on endosomal vacuoles (E) and endosomes that appear as multivesicular bodies (MVB), where it often colocalizes with the lysosomal membrane protein LIMP II. We also noted a colocalization of endobrevin with MPR46 in TGN-associated structures (B, arrowheads) and occasionally the appearance in coated pits/vesicles at the plasma membrane (C, arrow). Bars, 100 nm.
The resulting complex is very similar to the neuronal complex with respect to α-helical content, SDS and heat resistance, stoichiometry, and susceptibility to disassembly by NSF (Fasshauer et al., 1999; Yang et al., 1999), thus providing a convenient model for endobrevin–SNARE complexes.

Recombinant endobrevin was incubated with affinity-purified antibodies for 15 min and then combined with recombinant syntaxin 1 and SNAP-25 for the formation of ternary complexes. As a control, parallel incubations were performed with affinity-purified rabbit antibodies for synaptophysin, a major integral membrane protein of synaptic vesicles (Jahn et al., 1985; Wiedenmann and Franke, 1985). As shown in Figure 4 (middle lanes), incubation with endobrevin antibodies completely prevented the formation of SDS-resistant complexes. In contrast, complexes were formed when synaptophysin IgG was used or when the antibodies were omitted. Virtually identical results were obtained when Fab fragments instead of intact antibodies were used in the experiment (Figure 4, right lanes).

Next we investigated whether these Fab fragments had an effect on the in vitro fusion of early and late endosomes. For both fusion reactions, in vitro assays are available that were used here with slight modifications. PC12 cells were pre-loaded by endocytosis with complementary fluid-phase markers with the use of a 5-min pulse for the labeling of early endosomes and a 20-min pulse followed by a 60-min chase for the labeling of late endosomes. After homogenization, PNS were prepared and combined to initiate the in vitro fusion reaction. Upon fusion, the endocytosed markers form a complex that could be quantified. In some experiments, early and late endosomes were separated by sucrose density gradient centrifugation before the fusion assay.

The assays for homotypic fusion of early endosomes and late endosomes showed high ATP-dependent fusion activity (Table 2). In contrast, heterotypic fusion of early and late endosomes was inefficient regardless of whether early or late endosomes were labeled with biotinylated HRP or avidin, respectively. The activities were ~25% of late endosome activities, early and late endosomes were separated by sucrose density gradient centrifugation before the fusion assay.

The resulting complex is very similar to the neuronal complex with respect to α-helical content, SDS and heat resistance, stoichiometry, and susceptibility to disassembly by NSF (Fasshauer et al., 1999; Yang et al., 1999), thus providing a convenient model for endobrevin–SNARE complexes.
fusion activity and 15% of early endosome fusion activity (Table 2). These data show that early endosome and late endosome fusion are distinct fusion events with only minor cross-contamination, in agreement with earlier results (Aniento et al., 1993). For further confirmation, we analyzed the fused membrane vesicles by sucrose density gradient centrifugation. As shown in Figure 5, the fusion products of early and late endosome fusion were well separated. Furthermore, the fusion products of late endosome fusion comigrated with MPR300 but were devoid of cellubrevin, transferrin receptor, and synaptobrevin (our unpublished results), demonstrating that they are free of early endosomes and synaptic vesicles.

When endobrevin-specific antibodies (Fab fragments) were added 10 min before initiation of the reaction, a significant inhibition of fusion was observed: early endosome fusion was inhibited by ~50%, and late endosome fusion was inhibited by ~60% (Figure 6). Very similar results (early endosomes, 52% inhibition; late endosomes, 65% inhibition; data from a single experiment) were obtained when early and late endosomes were prepurified by sucrose gradient centrifugation. As a control, we used antibodies (Fab fragments) specific for synaptophysin, an abundant membrane protein of recycling organelles of neuroendocrine cells, including PC12 cells. These antibodies had no effect on the fusion of late endosomes and only a minor inhibitory effect on early endosome fusion (Figure 6) (see DISCUSSION). Preincubation of anti-endobrevin Fab fragments with stoichiometric amounts of recombinant endobrevin restored fusion activity (our unpublished results), confirming that inhibition of fusion by anti-endobrevin antibodies is due to specific interference with this protein.

It should be noted that inhibition of fusion was not complete. It is possible that antibody binding to endobrevin is inefficient because the protein is complexed to other SNAREs most of the time, forming cis complexes in the endosomal membrane. Because no ATP is present during the preincubation, such complexes would not be disassembled by NSF, resulting in protection of endobrevin from the inactivating antibody until the fusion reaction is initiated. Therefore, Fab fragment preincubation was carried out in the presence of ATP and cytosol as a source for NSF and SNAPs. However, the degree of inhibition did not increase significantly under these conditions, even when the concentrations of NSF and α-SNAP were increased by the addition of purified proteins (our unpublished results; see DISCUSSION).

**Table 2.** ATP-dependent fusion activities (HRP relative units) for early (EE) and late (LE) endosome preparations, labeled with either biotinylated HRP or avidin

<table>
<thead>
<tr>
<th></th>
<th>EE HRP</th>
<th>LE HRP</th>
</tr>
</thead>
<tbody>
<tr>
<td>EE avidin</td>
<td>322</td>
<td>41</td>
</tr>
<tr>
<td>LE avidin</td>
<td>47</td>
<td>181</td>
</tr>
</tbody>
</table>

The data are from a representative experiment. Early endosomes were labeled by 5 min of incubation, and late endosomes were labeled by 20 min of incubation followed by a 60-min chase period (see MATERIALS AND METHODS for details).
Fusion of early and late endosomes is inhibited by Fab fragments specific for endobrevin or by recombinant endobrevin. Fusion of early and late endosomes derived from PC12 cells was monitored in vitro with the use of a content-mixing assay (see MATERIALS AND METHODS). For preincubation of PNS, 1.2 μM Fab fragments specific for endobrevin (eb) or synaptophysin (syp) (left panels) or 30 μM soluble recombinant endobrevin or synaptobrevin (sb) (right panels) was used. ATP-dependent fusion activity in the absence of Fab fragments or recombinant protein is defined as 100%. Values are given as means of four independent experiments, and bars indicate the range. Fusion was initiated by mixing donor and acceptor fractions while simultaneously adding ATP and cytosol, followed by 30 min of incubation.

To confirm the role of endobrevin in early and late endosome fusion by an independent approach, we examined whether the addition of recombinant endobrevin inhibits fusion. As discussed above, the R-SNARE endobrevin is thought to form a complex with cognate SNARE partners during the fusion reaction. Excess amounts of the cytosolic part of endobrevin, therefore, are expected to compete with the endogenous protein. As shown in Figure 6 (right panels), recombinant endobrevin inhibited both fusion reactions as effectively as the Fab fragments. As a control, we added identical amounts of recombinant synaptobrevin, an R-SNARE functioning in exocytosis that is abundantly present on PC12 cell endosomes. No inhibition of either fusion reaction was observed. We conclude from these experiments that endobrevin functions as an R-SNARE in the fusion of two distinct intracellular fusion reactions.

DISCUSSION

In the present study, we have shown that endobrevin, an R-SNARE with a widespread distribution throughout the endocytic pathway, functions in the homotypic fusion of early and late endosomes.

Two independent approaches were chosen to investigate the role of endobrevin in endosome fusion, giving similar results. Antibodies are frequently used to inhibit the function of a protein in membrane fusion (McBride et al., 1999). However, it needs to be borne in mind that inhibition of fusion may be caused by the presence of bulky IgG molecules on the fusing membranes, thereby preventing membrane contact. An appropriate control for such indirect inhibition involves the use of antibodies specific for an abundant membrane protein of endosomes that is not involved in membrane fusion. Therefore, we chose PC12 cells, which, unlike neurons, abundantly express endobrevin, allowing us to use probes specific for synaptic vesicle proteins such as synaptophysin. Synaptophysin is highly abundant not only on exocytotic vesicles but also on early endosomes (Holroyd et al., 1999), providing a convenient control, at least for the fusion of early endosomes. Interestingly, intact IgG specific for synaptophysin (in contrast to Fab fragments) potently inhibited this fusion step (our unpublished observations), confirming that inhibition of in vitro fusion reactions may indeed be caused by such indirect effects.

It is noteworthy that the fusion reactions are inhibited by the addition of exogenous soluble endobrevin but not of synaptobrevin. In vitro, both endobrevin and synaptobrevin form SNARE complexes of similar structural properties with the same partner proteins (Fasshauer et al., 1999; Yang et al., 1999). The selectivity observed here supports the view that there must be at least some preference for the cognate SNARE. Preliminary observations suggest that this specificity may be overcome by the use of excessive amounts of synaptobrevin (our unpublished observations).

It remains to be established whether endobrevin is the only R-SNARE required for early and late endosome fusion or whether other, hitherto unidentified, R-SNAREs operate alongside endobrevin. The latter possibility is suggested by the observation that some fusion persisted in the presence of our antibodies, although these antibodies completely prevented assembly of endobrevin with Q-SNAREs in an in vitro assay. Interestingly, neurons do not express endobrevin (Advani et al., 1998; our unpublished observations), although fusion of early endosomes is thought to be involved in both synaptic and extrasynaptic trafficking pathways (Jessell and Kandel, 1993), suggesting the involvement of additional R-SNAREs. Cellubrevin, an abundant R-SNARE recycling between the plasma membrane and early endosomes, is not involved in early endosome fusion. Unlike endobrevin (our unpublished observations), cellubrevin is efficiently cleaved by clostridial neurotoxins, whereas endosome fusion is not affected by toxin treatment (Link et al., 1993; Holroyd et al. 1999). Rather, cellubrevin appears to function in the fusion of transport vesicles with the plasma membrane (Galli et al., 1994). Recently, VAMP-7, which is localized to late endosomes in addition to the TGN
and transport vesicles, has been suggested to operate in membrane traffic from the late endosome to the lysosome (Advani et al., 1999). Other candidates include VAMP-4, which was localized to endosomes (Steegmaier et al., 1999).

It is not yet known with which Q-SNAREs endobrevin interacts and whether its Q-SNARE partners are identical in the two fusion reactions. Recently, syntaxin 7 (Wong et al., 1998a) and syntaxin 12/13 (Advani et al., 1998; Tang et al., 1998) (syntaxin 12 and syntaxin 13 probably represent incomplete sequences of the same protein) have been localized to early endosomes, making them candidates for such Q-SNARE partners. Furthermore, syntaxin 13 was recently suggested to be involved in the fusion of early endosomes (McBride et al., 1999). In preliminary experiments, however, we were unable to coprecipitate endobrevin with syntaxin 13 from tissue extracts (our unpublished observations). Also, we were unable to coprecipitate endobrevin with syntaxin 7, suggesting that the SNARE complexes functioning in other intracellular fusion steps will soon be identified.

In conclusion, our data lend strong support to the view that the assembly of specific sets of SNARE proteins is involved in many, perhaps all, intracellular fusion steps. The ongoing characterization of new mammalian SNAREs raises the hope that the SNARE partners of endobrevin as well as the SNARE complexes functioning in other intracellular fusion steps will soon be identified.

ACKNOWLEDGMENTS

We are greatly indebted to Dr. C. Barnstable, Dr. E. Hartmann, Dr. A. Hille-Rehtfeld, and Dr. Y. Tenaka for their kind gifts of antibodies, and to Dr. D. Fasshauer and M. Margittai for the gift of recombinant SNAP-25, syntaxin1A, and synaptobrevin, respectively. We thank Dr. D. Bruns, Dr. D. Fasshauer, P. Holroyd, M. Margittai, S. Pabst, and B. Rammner for critically reading the manuscript and for fruitful discussions. This work was supported by grants from the Deutsche Forschungsgemeinschaft (SFB 532, TP A5, TP B6, TP Z2).

REFERENCES


